GlassScriptPhysician profile
Jamila Battle
NPI 1366560872
$12,635.20
in general payments reported to CMS, 2019-2025
16 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 87% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $352 · 2021: $36.16 · 2022: $640 · 2023: $7,834 · 2024: $672 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,813 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Food and Beverage: $1,677 · Education: $322 · Travel and Lodging: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,812.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Food and Beverage | $1,676.65 |
| Education | $321.91 |
| Travel and Lodging | $145.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $7,509.47 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $2,222.94 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $1,167.44 | 2019-2025 | |
| Harmony Biosciences LLC | $373.32 | 2020-2023 | Wakix |
| Axsome Therapeutics, INC. | $234.37 | 2024 | Sunosi |
| Indivior INC. | $226.90 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Inspire Medical Systems, INC. | $132.60 | 2022 | |
| Alkermes, INC. | $132.22 | 2019 | |
| Novo Nordisk INC | $124.22 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $122.32 | 2024 | Lumryz |
| Resmed Corp | $95.85 | 2022 | |
| Noctrix Health, INC. | $83.57 | 2024 | Nidra |
| Boston Scientific Corporation | $15.72 | 2025 | Wavewriter Alpha Prime 16 |
| Orexo US, INC. | $13.96 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $5.30 | 2025 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamila Battle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.